{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:08:56Z","timestamp":1781010536693,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020957","name":"Roche Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40123-026-01385-2","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T13:33:34Z","timestamp":1777124014000},"page":"1955-1971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid Effects on Anatomical and Functional Outcomes following Upload with Faricimab in Treatment-Na\u00efve nAMD: German Single-Center Study 45DRY"],"prefix":"10.1007","volume":"15","author":[{"given":"Maximilian","family":"Haase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Wittenborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"2","key":"1385_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et\u00a0al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"1385_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331(2):147\u201357.","journal-title":"JAMA"},{"issue":"1","key":"1385_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01554-2","volume":"20","author":"RP Finger","year":"2020","unstructured":"Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P. Anti-VEGF in nAMD\u2014Impact on outcomes and healthcare systems: a systematic review. BMC Ophthalmol. 2020;20(1):294.","journal-title":"BMC Ophthalmol"},{"key":"1385_CR4","doi-asserted-by":"publisher","first-page":"45081","DOI":"10.1038\/srep45081","volume":"7","author":"DS Ng","year":"2017","unstructured":"Ng DS, Yip YW, Bakthavatsalam M, Chen LJ, Ng TK, Lai TY, et\u00a0al. Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation. Sci Rep. 2017;7:45081.","journal-title":"Sci Rep"},{"issue":"8","key":"1385_CR5","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/IAE.0000000000003194","volume":"41","author":"PK Kaiser","year":"2021","unstructured":"Kaiser PK, Wykoff CC, Singh RP, Khanani AM, Do DV, Patel H, et\u00a0al. Retinal fluid and thickness as measures of disease activity in neovascular age-related macular degeneration. Retina. 2021;41(8):1579\u201386.","journal-title":"Retina"},{"issue":"1","key":"1385_CR6","doi-asserted-by":"publisher","first-page":"14166","DOI":"10.1038\/s41598-022-18158-z","volume":"12","author":"JH Kim","year":"2022","unstructured":"Kim JH, Sagong M, Woo SJ, Kim YC, Cho H, Lee YH, et\u00a0al. A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea. Sci Rep. 2022;12(1):14166.","journal-title":"Sci Rep"},{"issue":"5","key":"1385_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ophtha.2024.11.023","volume":"132","author":"CMG Cheung","year":"2025","unstructured":"Cheung CMG, Lim JI, Priglinger S, Querques G, Margaron P, Patel S, et\u00a0al. Anatomic outcomes with faricimab vs aflibercept in head-to-head dosing phase of the TENAYA\/LUCERNE trials in neovascular age-related macular degeneration. Ophthalmology. 2025;132(5):519\u201326.","journal-title":"Ophthalmology"},{"issue":"6","key":"1385_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamaophthalmol.2022.1357","volume":"140","author":"NS Patil","year":"2022","unstructured":"Patil NS, Mihalache A, Dhoot AS, Popovic MM, Muni RH, Kertes PJ. Association between visual acuity and residual retinal fluid following intravitreal anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: a systematic review and meta-analysis. JAMA Ophthalmol. 2022;140(6):611\u201322.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"1385_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jamaophthalmol.2019.4577","volume":"138","author":"MS Ramakrishnan","year":"2020","unstructured":"Ramakrishnan MS, Yu Y, VanderBeek BL. Association of visit adherence and visual acuity in patients with neovascular age-related macular degeneration: secondary analysis of the comparison of age-related macular degeneration treatment trial. JAMA Ophthalmol. 2020;138(3):237\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"1385_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S151611","volume":"12","author":"C Ehlken","year":"2018","unstructured":"Ehlken C, Helms M, B\u00f6hringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 2018;12:13\u201320.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"1385_CR11","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s40123-025-01140-z","volume":"14","author":"M Shellvarajah","year":"2025","unstructured":"Shellvarajah M, Nguyen V, Steinmann S, Gillies MC, Sagkriotis A, Barthelmes D. Adherence to anti-VEGF treatment in patients with neovascular age-related macular degeneration: a real-world study. Ophthalmol Ther. 2025;14(6):1261\u20139.","journal-title":"Ophthalmol Ther"},{"issue":"10326","key":"1385_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et\u00a0al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"key":"1385_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et\u00a0al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014. (Online ahead of print).","journal-title":"Ophthalmology"},{"issue":"10326","key":"1385_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et\u00a0al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355.","journal-title":"Lancet"},{"issue":"6","key":"1385_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et\u00a0al. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024;131(6):708\u201323.","journal-title":"Ophthalmology"},{"key":"1385_CR16","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, et\u00a0al. Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials. Ophthalmology. 2024;131:950\u201360.","journal-title":"Ophthalmology"},{"issue":"9","key":"1385_CR17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.oret.2025.03.005","volume":"9","author":"CJ Danzig","year":"2025","unstructured":"Danzig CJ, Dinah C, Ghanchi F, Hattenbach LO, Khanani AM, Lai TYY, et\u00a0al. Faricimab treat-and-extend dosing for macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials. Ophthalmol Retina. 2025;9(9):848\u201359.","journal-title":"Ophthalmol Retina"},{"issue":"5\u20136","key":"1385_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000541662","volume":"247","author":"PAH Nichani","year":"2024","unstructured":"Nichani PAH, Popovic MM, Mihalache A, Pathak A, Muni RH, Wong DTW, et\u00a0al. Efficacy and safety of intravitreal faricimab in nAMD, DME and RVO: a meta-analysis. Ophthalmologica. 2024;247(5\u20136):355\u201372.","journal-title":"Ophthalmologica"},{"issue":"4","key":"1385_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100744","volume":"5","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Guymer R, Artignan A, Downey A, Singh RP. Real-world evidence for faricimab in neovascular age-related macular degeneration and diabetic macular edema: a scoping review. Ophthalmol Sci. 2025;5(4):100744.","journal-title":"Ophthalmol Sci"},{"key":"1385_CR20","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.2147\/OPTH.S482948","volume":"18","author":"BC Kunzmann","year":"2024","unstructured":"Kunzmann BC, Schweig AS, Bartz-Schmidt KU, Sobolewska B. Real-world-data of treatment-na\u00efve and previously treated patients receiving up to 3 injections of faricimab in neovascular age-related macular degeneration. Clin Ophthalmol. 2024;18:4029\u201339.","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"1385_CR21","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1007\/s00417-024-06485-y","volume":"262","author":"W Aljundi","year":"2024","unstructured":"Aljundi W, Munteanu C, Seitz B, Abdin AD. Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262(9):2867\u201374.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1385_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040470","volume":"16","author":"W Aljundi","year":"2024","unstructured":"Aljundi W, Daas L, Suffo S, Seitz B, Abdin AD. First-year real-life experience with intravitreal faricimab for refractory neovascular age-related macular degeneration. Pharmaceutics. 2024;16(4):470.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1385_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10792-025-03525-2","volume":"45","author":"N Bleidi\u00dfel","year":"2025","unstructured":"Bleidi\u00dfel N, Weichenberger M, Maier M, Spielberg N, Feucht N. Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy. Int Ophthalmol. 2025;45(1):177.","journal-title":"Int Ophthalmol"},{"key":"1385_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15050189","author":"K L\u00f6w","year":"2025","unstructured":"L\u00f6w K, Sitnilska V, Tang Y, Lammert JQ, Krohne TU, Altay L. Real-life treatment intervals and morphological outcomes following the switch to faricimab therapy in neovascular age-related macular degeneration. J Pers Med. 2025. https:\/\/doi.org\/10.3390\/jpm15050189.","journal-title":"J Pers Med"},{"key":"1385_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020423","author":"P Wolfrum","year":"2025","unstructured":"Wolfrum P, B\u00f6hm EW, Lorenz K, Stoffelns B, Pfeiffer N, Korb CA. Clinical outcomes following a switch of therapy to faricimab in patients affected by neovascular age-related macular degeneration. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14020423.","journal-title":"J Clin Med"},{"issue":"9","key":"1385_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00347-025-02258-y","volume":"122","author":"B Heimes-Bussmann","year":"2025","unstructured":"Heimes-Bussmann B, Bellenbaum R, Njoo C, Liakopoulos S, Schmitz-Valckenberg S, Zortel M, et\u00a0al. Faricimab in previously treated neovascular age-related macular degeneration: study design of the prospective noninterventional study PASSENGER. Ophthalmologie. 2025;122(9):693\u20139.","journal-title":"Ophthalmologie"},{"issue":"5","key":"1385_CR27","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s40123-025-01125-y","volume":"14","author":"M Hafner","year":"2025","unstructured":"Hafner M, Asani B, Eckardt F, Siedlecki J, Schworm B, Priglinger SG. Deep-learning-assisted analysis of early biomarker changes in treatment-na\u00efve patients with neovascular AMD under intravitreal faricimab. Ophthalmol Ther. 2025;14(5):1025\u201337.","journal-title":"Ophthalmol Ther"},{"key":"1385_CR28","unstructured":"Bailey C, on behalf of the VOYAGER Investigators. Global real world clinical and anatomical outcomes with faricimab in treatment na\u00efve patients with neovascular age related macular degeneration and diabetic macular edema: the VOYAGER study. LB24\u2013166\u20134946. [oral presentation]. Presented at: EURETINA 2024 Congress; 2024 Sep 20; Barcelona, Spain. Available from: https:\/\/medically.gene.com\/global\/en\/unrestricted\/ophthalmology\/EURETINA-2024\/euretina-2024-presentation-bailey-global-real-world-cli.html. Accessed 25 Aug 2025."},{"key":"1385_CR29","unstructured":"Ophtha.ch. Visus-Umrechnung: ETDRS\u2014Snellen\u2014logMAR [Internet]. Bern: Ophtha Switzerland; c2020 [cited 2025 Nov 19]. https:\/\/ophtha.ch\/wiki\/visus-umrechnung-etdrs-snellen-logmar\/."},{"issue":"8","key":"1385_CR30","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1167\/iovs.02-1100","volume":"44","author":"DA Rosser","year":"2003","unstructured":"Rosser DA, Cousens SN, Murdoch IE, Fitzke FW, Laidlaw DA. How sensitive to clinical change are ETDRS logMAR visual acuity measurements? Invest Ophthalmol Vis Sci. 2003;44(8):3278\u201381.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1385_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100456","volume":"4","author":"K Kostolna","year":"2024","unstructured":"Kostolna K, Reiter GS, Frank S, Coulibaly LM, Fuchs P, R\u00f6ggla V, et\u00a0al. A systematic prospective comparison of fluid volume evaluation across OCT devices used in clinical practice. Ophthalmol Sci. 2024;4(3):100456.","journal-title":"Ophthalmol Sci"},{"issue":"17","key":"1385_CR32","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et\u00a0al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye (Lond). 2023;37(17):3574\u201381.","journal-title":"Eye (Lond)"},{"issue":"6","key":"1385_CR33","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41433-024-03532-0","volume":"39","author":"AA Aziz","year":"2025","unstructured":"Aziz AA, Khanani AM, Khan H, Lauer E, Khanani I, Mojumder O, et\u00a0al. Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study. Eye (Lond). 2025;39(6):1099\u2013106.","journal-title":"Eye (Lond)"},{"issue":"2","key":"1385_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, et\u00a0al. Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2019;126(2):252\u201360.","journal-title":"Ophthalmology"},{"issue":"9","key":"1385_CR35","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.ophtha.2016.05.016","volume":"123","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Kaiser PK, Thompson D, Gibson A, Saroj N, Vitti R, et\u00a0al. Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology. 2016;123(9):1856\u201364.","journal-title":"Ophthalmology"},{"issue":"1","key":"1385_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40942-024-00586-w","volume":"10","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M. Intravitreal faricimab for treatment na\u00efve patients with neovascular age-related macular degeneration: a real-world prospective study. Int J Retina Vitreous. 2024;10(1):70.","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"1385_CR37","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s41598-024-82746-4","volume":"15","author":"HY Han","year":"2025","unstructured":"Han HY, Park SM, Lee JH, Kim CG, Kim JW, Cho HJ, et\u00a0al. Outcomes and predictive factors for fluid resolution following three loading injections of faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Sci Rep. 2025;15(1):938.","journal-title":"Sci Rep"},{"issue":"9","key":"1385_CR38","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s40123-025-01204-0","volume":"14","author":"M Lupidi","year":"2025","unstructured":"Lupidi M, Iaculli C, Marco L, Rossi S, Sicari E, Villa G, et\u00a0al. Faricimab in the treatment of exudative neovascular age-related macular degeneration and diabetic macular edema in Italy: the FARIT real world study. Ophthalmol Ther. 2025;14(9):2197\u2013214.","journal-title":"Ophthalmol Ther"},{"issue":"9596","key":"1385_CR39","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"6","key":"1385_CR40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/aos.14698","volume":"99","author":"RP Finger","year":"2021","unstructured":"Finger RP, Daien V, Talks JS, Mitchell P, Wong TY, Sakamoto T, et\u00a0al. A novel tool to assess the quality of RWE to guide the management of retinal disease. Acta Ophthalmol. 2021;99(6):604\u201310.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"1385_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","volume":"12","author":"H Shahzad","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, Hubbard J, Haque S, Paudyal V, et\u00a0al. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev. 2023;12(1):92.","journal-title":"Syst Rev"},{"issue":"2","key":"1385_CR42","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C, et\u00a0al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128(2):234\u201347.","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01385-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01385-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01385-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:27:32Z","timestamp":1781008052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01385-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1385"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01385-2","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maximilian Haase has received speaker honoraria and research support from Roche Pharma AG. Esther Wittenborn is an employee of Roche Pharma AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This research was conducted in full compliance with the Guidelines for Good Pharmacoepidemiology Practice (GPP) published by the International Society of Pharmacoepidemiology (\n                      \n                      ), the laws and regulations in Germany as applicable, and the Declaration of Helsinki. The\u00a0research plan and relevant supporting information was approved by the competent Ethics Committee of the University Rostock on 2 May 2025 (A 2025\u20130115), before the research was initiated. All patients provided consent for the use and anonymization of the data and explicitly consented to any secondary use of their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}